Close menu

October 25th, 2023 | 07:20 CEST

BioNTech, Cardiol Therapeutics, Paion - Rising Attractiveness and Lots of Movement

  • Biotechnology
  • Innovations
  • Technology
Photo credits:

The current geopolitical uncertainties with escalating conflicts in Ukraine and Israel, as well as fears of recession with continued high inflation, have also impacted the capital-intensive biotech sector. In the past week, the Nasdaq Biotech Index fell to its lowest level of the year. Since the beginning of the year, the loss amounts to almost 12%. This level should offer excellent entry opportunities for long-term investors, as many biotech companies are currently very well-positioned and attractively valued.

time to read: 4 minutes | Author: Stefan Feulner

Table of contents:

    Paion with further sell-off

    One could be forgiven for thinking that the share chart of the biotech company, which was founded in Aachen, Germany, in 2000, is a good place to start. Following a capital reduction approved at the end of March, where each shareholder received one new share for ten old shares, the next measure has now been decided. The Company intends to raise a total of EUR 9 million through a rights issue to be used for investments in its commercial infrastructure, the European market launch of Byfavo in general anesthesia, product life cycle management, and the fulfillment of development obligations. In addition, the funds will be used for repayments and interest under the loan agreement with the European Investment Bank and for general corporate purposes.

    A look at the terms shows just how great the need appears to be. Thus, a total of 4.8 million shares at a price of EUR 1.90 will be offered to interested parties. Curiously, at the time of this announcement, the paion share was still at around EUR 3.75, nearly 100% higher compared to the subscription price.

    The only positive aspect is that the Chinese Humanwell Healthcare Group, "subject to certain conditions", undertakes to acquire new shares for a total amount of up to EUR 6 million. An exclusive remimazolam licensing agreement for the Chinese market has existed between Yichang Humanwell, a subsidiary of Humanwell, and paion since 2012. In addition, the Swiss investor Nice & Green also expressed interest and would acquire shares with a total value of EUR 5 million if the existing shareholders did not subscribe. However, this deal is also subject to certain conditions, which were not further explained in the current press release.

    The paion share is currently trading at EUR 2.25 and is dramatically approaching the subscription price of the new share. From our point of view, an investment is currently not advisable, even at the significantly lower level.

    Cardiol Therapeutics - Setback as an opportunity

    In the course of the general market correction in the biotech sector, as well as negative events such as the profit warning from the pharmaceutical giant Pfizer, the shares of the life sciences company Cardiol Therapeutics, which specializes in the research and clinical development of anti-inflammatory and anti-fibrotic therapeutics for the treatment of heart disease, also corrected. After hitting a high for the year at USD 1.24, the shares are consolidating at a 38% lower level at USD 0.76. However, the share price development does not correlate with the positive company performance of recent weeks, making it an attractive entry opportunity for long-term oriented investors. This perspective is shared by the Canadian investment house Leede Jones Gable, who, following positive study results in mid-October, issued a one-year price target of USD 3.28 with a "speculative buy" rating. This represents a price potential of around 375% relative to the current share price. Furthermore, Cardiol shares have impressively appreciated 441% year-to-date.

    At the 8th IIF-International Investment Forum, Cardiol’s CEO David Elsley explained the recent press release of study results presented by researchers from the Instituto Tecnológico de Monterrey in Mexico at the Heart Failure Society of America Annual Scientific Meeting 2023. The results demonstrated that subcutaneously administered cannabidiol, the active pharmaceutical ingredient in Cardiol's novel CRD-38 formulation, decelerates the increase in body and heart weight while also preventing undesirable increases in crucial inflammatory and remodeling markers of the heart.

    In addition, concerning the ARCHER trial, which focuses on acute myocarditis, Cardiol reported in mid-September that recruitment of the required patients is expected to be completed six months earlier than anticipated. The Company estimates that the 100 patients needed for the study will be recruited in the third quarter of the coming year. Furthermore, collaboration with all clinical research centers required for the study has been initiated.

    Another plus point for Cardiol Therapeutics compared to peer group companies is that the Company does not require any further capital measures for research and development until at least early 2026. As of June 30, 2023, the cash balance was CAD 45 million.

    BioNTech - Dangerous Situation

    The Mainz-based biotech company, BioNTech, is not likely to encounter financing problems in the near future, as the cash box is still bulging with income from the Corona vaccines. Instead, the problem here is that, due to the flattening of the pandemic, sales in the billions have been lost, which can hardly be **compensated by other preparations, such as cancer research, in the coming years. And the market cap is still a whopping USD 22 billion at a share price of around USD 91.

    BioNTech reported progress in one of its research projects. In a Phase II trial, the first patient with surgically removed pancreatic ductal adenocarcinoma was treated with the mRNA-based, individualized neoantigen-specific immunotherapy candidate Autogene cevumeran. A total of 260 patients are expected to participate in the Phase II clinical trial, which is being supported by BioNTech and Genentech. The focus of the collaboration is the global development, manufacturing and commercialization of innovative mRNA-based individualized cancer vaccines targeting neoantigens.

    The biotech sector is currently in a broad correction due to the current market environment. BioNTech is suffering from the sales warning of its partner Pfizer. At paion, a sell-off occurred due to the announcement of a capital increase significantly below market price. In contrast, analysts see a potential of around 375% for Cardiol Therapeutics following the announcement of positive study results.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET

    Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics

    • Biotechnology
    • Pharma

    Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.


    Commented by Armin Schulz on November 29th, 2023 | 06:30 CET

    MorphoSys, Cardiol Therapeutics, Bayer - Where will the rebound start first?

    • Biotechnology
    • Pharma

    2023 was a challenging year for pharmaceutical and biotech companies. After the boom years of the Corona pandemic, many companies went into a tailspin. But not just vaccine manufacturers were hit; others were dragged down too. The markets are currently volatile. MorphoSys has seen a peak gain of 145% since the beginning of the year - but is currently only up 35%. Cardiol Therapeutics has also gained over 140% and has recently consolidated. The share is currently up 74% since the beginning of the year. Only Bayer's performance curve is pointing downwards. The share is currently worth 34% less than on January 2. We look at where the rebound will start first after the consolidations.


    Commented by Armin Schulz on November 28th, 2023 | 06:45 CET

    ThyssenKrupp Nucera, Altech Advanced Materials, JinkoSolar - Green returns in focus

    • GreenTech
    • Batteries
    • Technology
    • renewableenergies

    GreenTech stocks have become an important topic in today's world. In the face of rising global environmental concerns and a growing awareness of sustainability, more and more investors are looking for investment opportunities that offer both financial returns and a positive impact on the environment. GreenTech stocks represent companies that are developing innovative technologies and solutions to address environmental issues and shape a sustainable future. Many countries have adopted policies to support the transition to a low-carbon economy. We have picked out three exciting companies.